Carisma Therapeutics Initiates Voluntary Delisting from Nasdaq
Carisma Therapeutics Inc. (OTCID: CARM) has made an important announcement regarding its future operations. The company's Board of Directors has approved a voluntary delisting of its common stock from The Nasdaq Stock Market. This decision reflects the company's desire to streamline its reporting obligations under the Securities and Exchange Act of 1934.
Reasons for the Delisting and Deregistration
The decision to proceed with the delisting stems from the company's previous noncompliance with Nasdaq's requirements related to bid prices and market value. Following a determination letter from Nasdaq, which underscored these issues, Carisma decided to take proactive steps to address its financial state. On October 13, 2025, the company’s common stock began trading on the OTCID market, shifting away from Nasdaq under the trading symbol "CARM." This transition showcases the company's adaptive strategy amid ongoing challenges.
The Impact of Delisting
Following the delisting, Carisma plans to file a Form 15 with the SEC to suspend its reporting requirements. By doing so, the company aims to alleviate the considerable burdens associated with sustaining its public company status. The anticipation is that the deregistration will take effect 90 days after this application is submitted, allowing for a more focused approach to winding down its operations.
Strategic Considerations Moving Forward
The Board has carefully weighed the benefits and implications of this decision. Among the factors considered were the timing of the Nasdaq determination letter, the utility of an expedited delisting process, and the overall direction of the company towards an orderly cessation of its operations. The aim is to maximize the company’s remaining resources for the benefit of its stakeholders, ensuring the most favorable outcome possible in a challenging situation.
About Carisma Therapeutics
Carisma Therapeutics has been recognized for its innovative approach to biotechnology, particularly in macrophage engineering aimed at addressing serious health conditions. The company’s vision has focused on developing transformative therapies for diseases such as liver fibrosis and cancer. As Carisma pivots towards winding down its business, its commitment to its mission remains evident.
Future Actions and Stakeholder Impact
In taking these steps, Carisma aims to maintain transparency with its stakeholders while focusing on financial health amidst operational challenges. Shareholders and other interested parties can rest assured that the company will be making its filings accessible through its website, ensuring continued open lines of communication during this transition.
Frequently Asked Questions
What is the reason for Carisma's delisting from Nasdaq?
Carisma's delisting is due to noncompliance with Nasdaq's bid price and market value requirements, leading the company to opt for a voluntary exit.
When did Carisma's common stock begin trading on the OTCID market?
The company's common stock started trading on the OTCID market on October 13, 2025, following its suspension from Nasdaq.
What are the next steps for Carisma following the delisting?
Carisma plans to file a Form 15 with the SEC to suspend its reporting obligations and will also pursue deregistration of its common stock subsequently.
How is Carisma planning to support its stakeholders during this transition?
The company is committed to maintaining transparency and will provide access to its filings on its website, prioritizing stakeholder communication.
What impact does this decision have on Carisma's business operations?
The delisting and deregistration are part of Carisma's strategy to wind down operations responsibly, optimizing its resources and managing liabilities effectively.
